Comparative Pharmacology
Head-to-head clinical analysis: PYOCIDIN versus XIFYRM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYOCIDIN versus XIFYRM.
PYOCIDIN vs XIFYRM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pyocidin is a bactericidal antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
XIFYRM is a monoclonal antibody that targets and neutralizes interleukin-36 (IL-36), thereby inhibiting the inflammatory signaling cascade involved in pustular psoriasis.
5 mg/kg intramuscular or subcutaneous every 24 hours. Max dose 300 mg per injection.
500 mg orally twice daily with food.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours in patients with normal renal function; extends to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 15 hours; prolonged in renal impairment (creatinine clearance <30 mL/min) to 30 hours
Primarily renal excretion of unchanged drug (60-70%), with 20-30% biliary excretion and minor fecal elimination (<10%).
Renal: 70% unchanged; Fecal: 20%; Biliary: <10%
Category C
Category C
Antibiotic
Antibiotic